Electronic Resource
أعرض في EDS

Intranasal sufentanil for cancer-associated breakthrough pain.

التفاصيل البيبلوغرافية
العنوان: Intranasal sufentanil for cancer-associated breakthrough pain.
المؤلفون: Good P., Ashby M., Jackson K., Brumley D.
بيانات النشر: SAGE Publications Ltd (55 City Road, London EC1Y 1SP, United Kingdom) United Kingdom 2012-10-13
نوع الوثيقة: Electronic Resource
مستخلص: The objective of this study was to demonstrate the efficacy, safety and patient acceptability of the use of intranasal sufentanil for cancer-associated breakthrough pain. This was a prospective, open label, observational study of patients in three inpatient palliative care units in Australia. Patients on opioids with cancer-associated breakthrough pain and clinical evidence of opioid responsiveness to their breakthrough pain were given intranasal (IN) Sufentanil via a GO MedicalTM patient controlled IN analgesia device. The main outcome measures were pain scores, need to revert to previous breakthrough opioid after 30 min, number of patients who chose to continue using IN sufentanil, and adverse effects. There were 64 episodes of use of IN sufentanil for breakthrough pain in 30 patients. There was a significant reduction in pain scores at 15 (P < 0.0001) and 30 min (P < 0.0001). In only 4/64 (6%) episodes of breakthrough pain did the participants choose to revert to their prestudy breakthrough medication. Twenty-three patients (77%) rated IN sufentanil as better than their prestudy breakthrough medication. The incidence of adverse effects was low and most were mild. Our study showed that IN sufentanil can provide relatively rapid onset, intense but relatively short lasting analgesia and in the palliative care setting it is an effective, practical, and safe option for breakthrough pain. © 2009 SAGE Publications.
مصطلحات الفهرس: open study, oxygen saturation, pain assessment, patient compliance, repeated drug dose, side effect/si [Side Effect], opiate/dt [Drug Therapy], sufentanil/ae [Adverse Drug Reaction], sufentanil/ct [Clinical Trial], sufentanil/do [Drug Dose], sufentanil/dt [Drug Therapy], sufentanil/na [Intranasal Drug Administration], human, drug delivery system, drug dose comparison, drug dose titration, drug efficacy, drug induced headache/si [Side Effect], drug safety, article, breathing rate, cancer pain/dt [Drug Therapy], cancer palliative therapy, clinical article, clinical trial, dose response, drowsiness/si [Side Effect], drug withdrawal, nausea/si [Side Effect], Article
URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31267
Click here for full text options
LibKey Link
الاتاحة: Open access content. Open access content
Copyright 2012 Elsevier B.V., All rights reserved.
Other Numbers: AUSHL oai:repository.monashhealth.org:1/31267
Palliative Medicine. 23 (1) (pp 54-58), 2009. Date of Publication: 2009.
0269-2163
https://repository.monashhealth.org/monashhealthjspui/handle/1/31267
19144765 [http://www.ncbi.nlm.nih.gov/pubmed/?term=19144765]
354095058
(Good) Calvary Mater Newcastle, University of Newcastle, Callaghan, NSW, Australia (Jackson) Southern Health and Monash University, Monash Medical Centre, McCulloch House, Clayton, VIC, Australia (Brumley) Ballarat Health Services, Ballarat, VIC, Australia (Ashby) Royal Hobart Hospital, Department of Health and Human Services, Repatriation Centre, Hobart, TAS, Australia (Good) Calvary Mater Newcastle, Department of Palliative Care, Hunter Region Mail Centre, Locked Bag 7, Warabrook, NSW 2310, Australia
Good P.; phillip.good@mater.health.nsw.gov.au
1305123801
المصدر المساهم: MONASH HEALTH LIBRS
From OAIster®, provided by the OCLC Cooperative.
رقم الانضمام: edsoai.on1305123801
قاعدة البيانات: OAIster
ResultId 1
Header edsoai
OAIster
edsoai.on1305123801
765
3
Electronic Resource
electronicResource
765.288696289063
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1305123801&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://repository.monashhealth.org/monashhealthjspui/handle/1/31267# [Name] => EDS - OAIster [Category] => fullText [Text] => View record in OAIster [MouseOverText] => View record in OAIster ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Intranasal sufentanil for cancer-associated breakthrough pain. )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Good+P%2E%22&quot;&gt;Good P.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ashby+M%2E%22&quot;&gt;Ashby M.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jackson+K%2E%22&quot;&gt;Jackson K.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Brumley+D%2E%22&quot;&gt;Brumley D.&lt;/searchLink&gt; )
Array ( [Name] => PublisherInfo [Label] => Publisher Information [Group] => [Data] => SAGE Publications Ltd (55 City Road, London EC1Y 1SP, United Kingdom) United Kingdom 2012-10-13 )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => Electronic Resource )
Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => The objective of this study was to demonstrate the efficacy, safety and patient acceptability of the use of intranasal sufentanil for cancer-associated breakthrough pain. This was a prospective, open label, observational study of patients in three inpatient palliative care units in Australia. Patients on opioids with cancer-associated breakthrough pain and clinical evidence of opioid responsiveness to their breakthrough pain were given intranasal (IN) Sufentanil via a GO MedicalTM patient controlled IN analgesia device. The main outcome measures were pain scores, need to revert to previous breakthrough opioid after 30 min, number of patients who chose to continue using IN sufentanil, and adverse effects. There were 64 episodes of use of IN sufentanil for breakthrough pain in 30 patients. There was a significant reduction in pain scores at 15 (P &lt; 0.0001) and 30 min (P &lt; 0.0001). In only 4/64 (6%) episodes of breakthrough pain did the participants choose to revert to their prestudy breakthrough medication. Twenty-three patients (77%) rated IN sufentanil as better than their prestudy breakthrough medication. The incidence of adverse effects was low and most were mild. Our study showed that IN sufentanil can provide relatively rapid onset, intense but relatively short lasting analgesia and in the palliative care setting it is an effective, practical, and safe option for breakthrough pain. &#169; 2009 SAGE Publications. )
Array ( [Name] => Subject [Label] => Index Terms [Group] => Su [Data] => &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22open+study%22&quot;&gt;open study&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22oxygen+saturation%22&quot;&gt;oxygen saturation&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22pain+assessment%22&quot;&gt;pain assessment&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22patient+compliance%22&quot;&gt;patient compliance&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22repeated+drug+dose%22&quot;&gt;repeated drug dose&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22side+effect%2Fsi+[Side+Effect]%22&quot;&gt;side effect/si [Side Effect]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22opiate%2Fdt+[Drug+Therapy]%22&quot;&gt;opiate/dt [Drug Therapy]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22sufentanil%2Fae+[Adverse+Drug+Reaction]%22&quot;&gt;sufentanil/ae [Adverse Drug Reaction]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22sufentanil%2Fct+[Clinical+Trial]%22&quot;&gt;sufentanil/ct [Clinical Trial]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22sufentanil%2Fdo+[Drug+Dose]%22&quot;&gt;sufentanil/do [Drug Dose]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22sufentanil%2Fdt+[Drug+Therapy]%22&quot;&gt;sufentanil/dt [Drug Therapy]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22sufentanil%2Fna+[Intranasal+Drug+Administration]%22&quot;&gt;sufentanil/na [Intranasal Drug Administration]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22human%22&quot;&gt;human&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drug+delivery+system%22&quot;&gt;drug delivery system&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drug+dose+comparison%22&quot;&gt;drug dose comparison&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drug+dose+titration%22&quot;&gt;drug dose titration&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drug+efficacy%22&quot;&gt;drug efficacy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drug+induced+headache%2Fsi+[Side+Effect]%22&quot;&gt;drug induced headache/si [Side Effect]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drug+safety%22&quot;&gt;drug safety&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22article%22&quot;&gt;article&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22breathing+rate%22&quot;&gt;breathing rate&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22cancer+pain%2Fdt+[Drug+Therapy]%22&quot;&gt;cancer pain/dt [Drug Therapy]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22cancer+palliative+therapy%22&quot;&gt;cancer palliative therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22clinical+article%22&quot;&gt;clinical article&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22clinical+trial%22&quot;&gt;clinical trial&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22dose+response%22&quot;&gt;dose response&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drowsiness%2Fsi+[Side+Effect]%22&quot;&gt;drowsiness/si [Side Effect]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22drug+withdrawal%22&quot;&gt;drug withdrawal&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22nausea%2Fsi+[Side+Effect]%22&quot;&gt;nausea/si [Side Effect]&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Article%22&quot;&gt;Article&lt;/searchLink&gt; )
Array ( [Name] => URL [Label] => URL [Group] => URL [Data] => &lt;externalLink term=&quot;https://repository.monashhealth.org/monashhealthjspui/handle/1/31267&quot;&gt;https://repository.monashhealth.org/monashhealthjspui/handle/1/31267&lt;/externalLink&gt;&lt;br /&gt;Click here for full text options&lt;br /&gt;LibKey Link )
Array ( [Name] => Avail [Label] => Availability [Group] => [Data] => Open access content. Open access content&lt;br /&gt;Copyright 2012 Elsevier B.V., All rights reserved. )
Array ( [Name] => NumberOther [Label] => Other Numbers [Group] => [Data] => AUSHL oai:repository.monashhealth.org:1/31267&lt;br /&gt;Palliative Medicine. 23 (1) (pp 54-58), 2009. Date of Publication: 2009.&lt;br /&gt;0269-2163&lt;br /&gt;https://repository.monashhealth.org/monashhealthjspui/handle/1/31267&lt;br /&gt;19144765 [http://www.ncbi.nlm.nih.gov/pubmed/?term=19144765]&lt;br /&gt;354095058&lt;br /&gt;(Good) Calvary Mater Newcastle, University of Newcastle, Callaghan, NSW, Australia (Jackson) Southern Health and Monash University, Monash Medical Centre, McCulloch House, Clayton, VIC, Australia (Brumley) Ballarat Health Services, Ballarat, VIC, Australia (Ashby) Royal Hobart Hospital, Department of Health and Human Services, Repatriation Centre, Hobart, TAS, Australia (Good) Calvary Mater Newcastle, Department of Palliative Care, Hunter Region Mail Centre, Locked Bag 7, Warabrook, NSW 2310, Australia&lt;br /&gt;Good P.; phillip.good@mater.health.nsw.gov.au&lt;br /&gt;1305123801 )
Array ( [Name] => OtherAuthors [Label] => Contributing Source [Group] => [Data] => MONASH HEALTH LIBRS&lt;br /&gt;From OAIster&#174;, provided by the OCLC Cooperative. )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsoai.on1305123801 )
RecordInfo Array ( [BibEntity] => Array ( [Titles] => Array ( [0] => Array ( [TitleFull] => Intranasal sufentanil for cancer-associated breakthrough pain. [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Good P. ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Ashby M. ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jackson K. ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Brumley D. ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Good P. ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Ashby M. ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jackson K. ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Brumley D. ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2012 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-locals [Value] => edsoaiOpen ) ) ) ) ) ) )
IllustrationInfo